|
Apr 16
|
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
|
|
Apr 15
|
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
|
|
Apr 9
|
Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround
|
|
Apr 9
|
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
|
|
Apr 6
|
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
|
|
Apr 1
|
Million-Dollar Bets: 3 Under-$15 Stocks With Massive Potential
|
|
Mar 26
|
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
|
|
Mar 13
|
Q4 2023 Clearside Biomedical Inc Earnings Call
|
|
Mar 12
|
Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 34.74%: Read This Before Placing a Bet
|
|
Mar 11
|
Ocular Therapeutix Inc Reports Growth Amidst Strategic Shifts
|
|
Mar 11
|
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
|
|
Mar 11
|
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
|
|
Mar 5
|
Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
|
|
Feb 26
|
Are You Looking for a Top Momentum Pick? Why Ocular Therapeutix (OCUL) is a Great Choice
|
|
Feb 26
|
Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Feb 22
|
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
|
|
Feb 22
|
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
|
|
Feb 22
|
Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
|
|
Feb 21
|
Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 64.63%: Here's is How to Trade
|
|
Jan 30
|
Does Ocular Therapeutix (OCUL) Have the Potential to Rally 134.83% as Wall Street Analysts Expect?
|